Drug profile · INN
cabergoline
CABASER
cabergoline (CABASER) is a dopamine d2 receptor agonist. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — cabergoline
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 1
- Data quality
- 0.89
Quick answer
cabergoline (CABASER) is a dopamine d2 receptor agonist. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dopamine D2 receptor agonist
Primary target: D(2) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12391663
Isoindolinone compounds
granted -
US 12378199
Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules
granted -
US 12263143
Ionic channel modulation as a method for treating tumors through inflammasome activation
granted -
US 12070628
Low energy immune priming for treating cancer and metastasis
granted -
US 12011619
Low intensity focused ultrasound for treating cancer and metastasis
granted -
US 11912682
Isoindolinone compounds
granted -
US 11344631
Promoter for cell-specific gene expression and uses thereof
granted -
US 11279922
Delivery of therapeutic agents by a collagen binding protein
granted -
US 11246858
Immunoresponsive methods of treating tumors
granted -
US 11001820
Delivery of therapeutic agents by a collagen binding protein
granted -
US 10974077
Low intensity focused ultrasound for treating cancer and metastasis
granted -
US 10772846
Methods and compositions for treating and preventing arthritis
granted -
US 10519138
Modulators of SOCE, compositions, and uses thereof
granted -
US 10213488
Delivery of therapeutic agents by a collagen binding protein
granted -
US 10104882
Methods and compositions for preventing and treating electrophile-mediated toxicities
granted -
US 9579273
Delivery of therapeutic agents by a collagen binding protein
granted -
US 9556438
Gene vector
granted -
US 9526765
Delivery of therapeutic agents by a collagen binding protein
granted -
US 8835510
Methods and compositions for treating conditions mediated by oxidative stress or electrophilic environmental toxins
granted -
US 8574653
Intermittent flow extrusion process and food product
granted
Frequently asked questions
What is cabergoline?
cabergoline (CABASER) is a dopamine d2 receptor agonist. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for cabergoline?
CABASER is a marketed brand name for cabergoline. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cabergoline?
cabergoline has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.